<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713113</url>
  </required_header>
  <id_info>
    <org_study_id>250</org_study_id>
    <nct_id>NCT02713113</nct_id>
  </id_info>
  <brief_title>Efficacy of Low Dose Sugammadex in Reversal of NMB in Laparoscopic Barbaric Surgery</brief_title>
  <official_title>Comparison of Three Different Doses Sugammadex Based on Ideal Body Weight for Reversal of Moderate Rocuronium-induced Neuromuscular Blockade in Laparoscopic Bariatric Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the investigators aimed to compare the efficacy and safety of sugammadex at doses of 1.5, 2,
      and 4 mg/ kg for the reversal of moderate rocuronium-induced neuromuscular blockade in
      laparoscopic bariatric surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomly assigned using a randomization-computer program into three groups
      according to the dose of sugammadex administrated (according to the IBW after T2 of TOF):

      Group I: patients were given 1.5 mg / kg. Group II: patients were given 2 mg / kg. Group III:
      patients were given 4 mg / kg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sugammadex time following a dose of 1.5 mg / kg of sugammadex according to IBW in comparison to 2, and 4 mg / kg,</measure>
    <time_frame>2 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>extubation time</measure>
    <time_frame>2 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Bariatric Patients</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients were given 1.5 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients were given 2 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients were given 4 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugammadex reversal of neuromuscular blockade</intervention_name>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group II</arm_group_label>
    <arm_group_label>group III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  morbidly obese patients of both sex (BMI &gt; 40 kg.m-2)

          -  scheduled for elective laparoscopic bariatric surgery (gastric bypass or sleeve
             surgery) under general anesthesia using rocuronium for tracheal intubation and
             maintenance of NMB

          -  aged between 18 and 60 years and classified as ASA II - III

        Exclusion Criteria:

          -  liver and renal dysfunction,

          -  disabling neuropsychiatric disorders,

          -  history of stroke, brain trauma in the last 12 months

          -  hypersensitivity to anesthetics, history of myocardial infarction, congestive heart
             failure

          -  difficult tracheal intubation, and known or suspected disorder affecting NMB.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed H Othman, MD</last_name>
    <role>Study Director</role>
    <affiliation>ASSUIT UNVERSITY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Egypt Cancer Instuite</name>
      <address>
        <city>Assuit</city>
        <zip>171516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>March 18, 2016</last_update_submitted>
  <last_update_submitted_qc>March 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Fatma Adel El sherif</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

